1391 related articles for article (PubMed ID: 12039933)
1. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
3. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
Nanda R; Schumm LP; Cummings S; Fackenthal JD; Sveen L; Ademuyiwa F; Cobleigh M; Esserman L; Lindor NM; Neuhausen SL; Olopade OI
JAMA; 2005 Oct; 294(15):1925-33. PubMed ID: 16234499
[TBL] [Abstract][Full Text] [Related]
4. Assessing BRCA carrier probabilities in extended families.
Barcenas CH; Hosain GM; Arun B; Zong J; Zhou X; Chen J; Cortada JM; Mills GB; Tomlinson GE; Miller AR; Strong LC; Amos CI
J Clin Oncol; 2006 Jan; 24(3):354-60. PubMed ID: 16421416
[TBL] [Abstract][Full Text] [Related]
5. High prevalence of BRCA1 deletions in BRCAPRO-positive patients with high carrier probability.
Veschi S; Aceto G; Scioletti AP; Gatta V; Palka G; Cama A; Mariani-Costantini R; Battista P; Calò V; Barbera F; Bazan V; Russo A; Stuppia L
Ann Oncol; 2007 Jun; 18 Suppl 6():vi86-92. PubMed ID: 17591842
[TBL] [Abstract][Full Text] [Related]
6. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy.
Stuppia L; Di Fulvio P; Aceto G; Pintor S; Veschi S; Gatta V; Colosimo A; Cianchetti E; Cama A; Mariani-Costantini R; Battista P; Palka G
Hum Mutat; 2003 Aug; 22(2):178-9. PubMed ID: 12872265
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.
Vogel KJ; Atchley DP; Erlichman J; Broglio KR; Ready KJ; Valero V; Amos CI; Hortobagyi GN; Lu KH; Arun B
J Clin Oncol; 2007 Oct; 25(29):4635-41. PubMed ID: 17925560
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
Capalbo C; Ricevuto E; Vestri A; Ristori E; Sidoni T; Buffone O; Adamo B; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
Ann Oncol; 2006 Jun; 17 Suppl 7():vii34-40. PubMed ID: 16760289
[TBL] [Abstract][Full Text] [Related]
10. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
Euhus DM; Smith KC; Robinson L; Stucky A; Olopade OI; Cummings S; Garber JE; Chittenden A; Mills GB; Rieger P; Esserman L; Crawford B; Hughes KS; Roche CA; Ganz PA; Seldon J; Fabian CJ; Klemp J; Tomlinson G
J Natl Cancer Inst; 2002 Jun; 94(11):844-51. PubMed ID: 12048272
[TBL] [Abstract][Full Text] [Related]
11. Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
Chen S; Iversen ES; Friebel T; Finkelstein D; Weber BL; Eisen A; Peterson LE; Schildkraut JM; Isaacs C; Peshkin BN; Corio C; Leondaridis L; Tomlinson G; Dutson D; Kerber R; Amos CI; Strong LC; Berry DA; Euhus DM; Parmigiani G
J Clin Oncol; 2006 Feb; 24(6):863-71. PubMed ID: 16484695
[TBL] [Abstract][Full Text] [Related]
12. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
de la Hoya M; Osorio A; Godino J; Sulleiro S; Tosar A; Perez-Segura P; Fernandez C; Rodríguez R; Díaz-Rubio E; Benítez J; Devilee P; Caldés T
Int J Cancer; 2002 Feb; 97(4):466-71. PubMed ID: 11802208
[TBL] [Abstract][Full Text] [Related]
13. Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer.
Chang-Claude J; Becher H; Caligo M; Eccles D; Evans G; Haites N; Hodgson S; Møller P; Weber BH; Stoppa-Lyonnet D
Dis Markers; 1999 Oct; 15(1-3):53-65. PubMed ID: 10595253
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
15. Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations.
Marroni F; Aretini P; D'Andrea E; Caligo MA; Cortesi L; Viel A; Ricevuto E; Montagna M; Cipollini G; Federico M; Santarosa M; Marchetti P; Bailey-Wilson JE; Bevilacqua G; Parmigiani G; Presciuttini S
Eur J Hum Genet; 2004 Nov; 12(11):899-906. PubMed ID: 15340362
[TBL] [Abstract][Full Text] [Related]
16. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
Antoniou AC; Hardy R; Walker L; Evans DG; Shenton A; Eeles R; Shanley S; Pichert G; Izatt L; Rose S; Douglas F; Eccles D; Morrison PJ; Scott J; Zimmern RL; Easton DF; Pharoah PD
J Med Genet; 2008 Jul; 45(7):425-31. PubMed ID: 18413374
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
Eoh KJ; Park JS; Park HS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
Gynecol Oncol; 2017 Apr; 145(1):137-141. PubMed ID: 28159408
[TBL] [Abstract][Full Text] [Related]
18. Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer.
Sugano K; Nakamura S; Ando J; Takayama S; Kamata H; Sekiguchi I; Ubukata M; Kodama T; Arai M; Kasumi F; Hirai Y; Ikeda T; Jinno H; Kitajima M; Aoki D; Hirasawa A; Takeda Y; Yazaki K; Fukutomi T; Kinoshita T; Tsunematsu R; Yoshida T; Izumi M; Umezawa S; Yagata H; Komatsu H; Arimori N; Matoba N; Gondo N; Yokoyama S; Miki Y
Cancer Sci; 2008 Oct; 99(10):1967-76. PubMed ID: 19016756
[TBL] [Abstract][Full Text] [Related]
19. The BOADICEA model of genetic susceptibility to breast and ovarian cancer.
Antoniou AC; Pharoah PP; Smith P; Easton DF
Br J Cancer; 2004 Oct; 91(8):1580-90. PubMed ID: 15381934
[TBL] [Abstract][Full Text] [Related]
20. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]